Migraine and Depression Share Common Neuropeptide Pathways — CGRP, Substance P, and Neuropeptide Y

Migraine and depression share overlapping biological mechanisms involving CGRP, PACAP, substance P, neuropeptide Y, orexins, serotonin, sex hormones, and immune pathways — explaining their strong bidirectional clinical relationship.

Viudez-Martínez, Adrián et al.·Biomolecules·2024·Moderate EvidenceReview
RPEP-09449ReviewModerate Evidence2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
N=N/A (review)
Participants
Patients with comorbid migraine and depression (general review)

What This Study Found

Multiple neuropeptide systems (CGRP, PACAP, substance P, neuropeptide Y, orexins) provide overlapping biological substrates for both migraine and depression, explaining their strong bidirectional clinical relationship.

Key Numbers

Migraine patients are 2.5x more likely to develop depression; risk is higher in chronic migraine and migraine with aura; bidirectional relationship.

How They Did This

Comprehensive narrative review of epidemiological, clinical, and molecular evidence linking migraine and depression through shared biological mechanisms.

Why This Research Matters

Treating migraine without addressing depression (and vice versa) leads to poorer outcomes. Understanding shared neuropeptide mechanisms could enable dual-action therapies — drugs that treat both conditions by targeting common pathways like CGRP or PACAP.

The Bigger Picture

The neuropeptide overlap between migraine and depression suggests that anti-CGRP therapies may have unexplored mood benefits, and that depression treatments targeting shared peptide systems could improve migraine. This reframes both conditions as part of a shared neuropeptide dysregulation spectrum.

What This Study Doesn't Tell Us

Narrative review — no new data. Causation vs correlation for shared mechanisms is difficult to establish. Not all migraine patients have depression and vice versa. Individual neuropeptide contributions to each condition are not fully quantified.

Questions This Raises

  • ?Do anti-CGRP migraine therapies improve depressive symptoms in comorbid patients?
  • ?Could PACAP-targeting drugs treat both migraine and depression simultaneously?
  • ?Should psychiatric screening be mandatory for all chronic migraine patients?

Trust & Context

Key Stat:
2.5× depression risk in migraine Shared neuropeptide mechanisms (CGRP, PACAP, substance P, NPY, orexins) explain this strong bidirectional association
Evidence Grade:
Moderate evidence — well-supported review integrating epidemiological data with mechanistic evidence from multiple neuropeptide systems.
Study Age:
Published in 2024. Integrates latest neuropeptide research including CGRP and PACAP findings.
Original Title:
Understanding the Biological Relationship between Migraine and Depression.
Published In:
Biomolecules, 14(2) (2024)
Database ID:
RPEP-09449

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Why do so many people with migraines also have depression?

Because the two conditions share the same brain chemical pathways. Neuropeptides like CGRP (the target of new migraine drugs), substance P, and neuropeptide Y are involved in both pain processing and mood regulation. When these systems are disrupted, both migraine and depression can result.

Could migraine drugs help with depression too?

Possibly — since CGRP and other neuropeptides targeted by migraine therapies also play roles in mood, treating one condition might benefit the other. Some migraine patients report mood improvements on CGRP antibodies, but this hasn't been formally studied in depression trials yet.

Read More on RethinkPeptides

Cite This Study

RPEP-09449·https://rethinkpeptides.com/research/RPEP-09449

APA

Viudez-Martínez, Adrián; Torregrosa, Abraham B; Navarrete, Francisco; García-Gutiérrez, María Salud. (2024). Understanding the Biological Relationship between Migraine and Depression.. Biomolecules, 14(2). https://doi.org/10.3390/biom14020163

MLA

Viudez-Martínez, Adrián, et al. "Understanding the Biological Relationship between Migraine and Depression.." Biomolecules, 2024. https://doi.org/10.3390/biom14020163

RethinkPeptides

RethinkPeptides Research Database. "Understanding the Biological Relationship between Migraine a..." RPEP-09449. Retrieved from https://rethinkpeptides.com/research/viudez-martinez-2024-understanding-the-biological-relationship

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.